Mirivadelgat
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
WINDWARD NCT06475781 · Group 3 Pulmonary Hypertension Registry: NCT06475781 | 2 | Pulmonary Vascular Resistance (PVR) (12 weeks) 2028-02 | In progress: results expected 1 Feb 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mirivadelgat: this drug | Phase 2 | Small molecule | ALDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Mosliciguat | Phase 3 | Small molecule | Soluble guanylate cyclase | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Fc-Relaxin Fusion Protein (TX45) | Phase 2 | Protein / enzyme therapeutic | Relaxin receptor (RXFP1) / relaxin | not yet graded | No reviewed efficacy summary in this indication | |
| LAM-001 | Phase 2 | Small molecule | mTOR (inhibitor) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Mirivadelgat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.